Phase 3 Head and Neck Cancer Trial, Recruiting NCT05877872 Sponsor: Sun Yat-sen University Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 3 Head and Neck Cancer Trial, Recruiting

NCT05877872
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your nasopharyngeal cancer (cancer in the back of the nose/throat) came back more than 6 months after you finished radiation therapy.
  • A tissue sample (biopsy) has confirmed that your nasopharyngeal cancer has returned.
  • Your returned cancer is considered removable by surgery, based on its size and location — including certain cases where the tumor is near a major blood vessel, provided that vessel has been treated beforehand (confirm with trial site).
  • After receiving 3 cycles of a specific combination of chemotherapy and immunotherapy before surgery, your cancer shrank by at least a certain amount as measured by scans.
  • You are willing and able to sign a consent form agreeing to take part.

Who may not be able to join:

  • Your general health and ability to carry out daily activities is rated too low on a standard health scale (confirm with trial site).
  • You have serious problems with major organs, a severe ongoing illness, or a significant history of mental health conditions.
  • Your tumor is located only on the roof or back wall of the throat area, where this type of surgery would not be expected to help.
  • You have cancer that has returned in the lymph nodes in your neck and has spread into nearby bones or major blood vessels, making surgery not possible.
  • Your cancer has spread to other parts of your body (metastatic disease).
  • You have or have had another type of cancer, unless it was a fully cured form of skin cancer or a very early-stage cervical condition.
  • You have taken steroid medications (such as cortisone or prednisone) within the 4 weeks before the planned start of treatment.
  • You have a condition that requires long-term use of drugs that suppress the immune system, or you need high-dose steroid treatment regularly.
  • You have previously been treated with certain types of immunotherapy drugs (PD-1, PD-L1, or CTLA-4 blocking treatments).
  • You have an active autoimmune disease — meaning your immune system is currently attacking your own body (for example, certain eye, gut, liver, kidney, or thyroid conditions). Note: some mild skin conditions that do not need systemic treatment may still be allowed (confirm with trial site).
  • You have HIV, a certain level of active Hepatitis B infection, or a positive test for Hepatitis C antibodies.
  • You have received a live vaccine within 4 weeks before the planned start of treatment, or you are currently pregnant or breastfeeding.
  • You are unable to attend regular follow-up appointments.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ming-Yuan Chen, MD, PhD, Sun Yat-sen University

Phone: 86-20-8734-3361

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
20 May 2023
Est. completion
30 March 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Overall Survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov